Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Ovarian cancer Clinical Trials

Protocol Number Title
2006LS032
MT2005-21 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
2006NT001
WCC 60 Biomarker with Biological Function in Ovarian Carcinoma/Diagnostic Markers for Ovarian Cancer: Detection of Novel Cell Adhesion Proteins in Patients' Specimens
2011NTLS157
Use of Pap test samples to study human diseases
2013NTLS041
A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy
2013NTLS073
Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients: A Randomized Controlled Trial
2014IS090
A Phase I/II safety, pharmacokinetic, and pharmacodynamic study of APS001F with flucytosine and maltose for the treatment of advanced and/or metastatic solid tumors.
2014NTLS003
Identification of Changes in Gene Expression of Epithelial Ovarian Cancer Tumors after Neoadjuvant Chemotherapy: Application of RNA-Seq Transcriptome Analysis, a Pilot Study
2014NTLS069
Personalized mouse models of chemotherapy resistance in ovarian cancer
2015NTLS018
MT2015-08R: Microbial, Graft and Host Interactions in Hematopoietic Cell Transplantation Reducing sepsis-related mortality in cancer patients through microbiome therapy
2016CG029
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) NRG-GY005
2016IS065
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
2016IS181
Phase II randomized study of pembrolizumab with or without epigenetic modulation with CC-486 in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
2016IS192
A Phase 1, Open-Label, Multicenter, Dose escalation study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection to patients with advanced malignancies
2016LS034
Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only after 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
2016LS186
MT2017-14 :Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) with Intraperitoneal Interleukin-2 in Women with Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
2016NTLS035
Solid Tumor Cancer Specimen Bank
2016NTLS144
The Development of Data Capture Methodologies in Pediatric Cancer Patients Treated with Targeted Agents and Immunotherapies: Leveraging the Research Infrastructure of a Childhood Cancer Survivor Program
2016NTLS151
Cytomegalovirus Status and Adaptive Natural Killer Cells in Ovarian Cancer: A Pilot Study
2016NTLS163
Development Of A Clinical Precision Medicine Program In Ovarian Cancer As A Paradigm For 21st Century Tailored-Health Care Solutions
2016NTLS175
Gynecologic Oncology Life after Diagnosis (GOLD) Survivorship Cohort
2017CG114
COG APEC1621 - NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) MASTER VERSION CONTROL PROTOCOL
2017IS028
Phase 1 Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNβ-NIS) Monotherapy and in Combination with Avelumab, in Patients with Refractory Solid Tumors
2017IS061
MT2017-36 :FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors
2017IS090
A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer
2018CG089
COG AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
2018CG118
COG AGCT1532 - A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors
2018IS003
A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH NKTR-214 AND IN COMBINATION WITH NKTR-214 PLUS NIVOLUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
2018NTIS113
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
EAY131-Z1C
EAY131-Z1C: MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1I
EAY131-Z1I: MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
PEDS-2017-26277
Outcomes and Survivorship in Pediatric Germ Cell Tumors

31 trials displayed